stockportfolio.pro
Pacira BioSciences, Inc. (PCRX)
Healthcare · Drug Manufacturers - Specialty & Generic · NasdaqGS
Pacira BioSciences, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $276.37M | $286.63M | $337.28M | $421.03M | $429.65M | $541.53M | $666.82M | $674.98M | $700.97M | $726.41M |
| Gross profit | $166.27M | $198.72M | $250.43M | $314.31M | $312.32M | $401.28M | $467.53M | $490.31M | $530.54M | $576.66M |
| Net income | $-37.95M | $-42.61M | $-471,000 | $-11.02M | $145.52M | $41.98M | $15.91M | $41.95M | $-99.56M | $7.03M |
| Net margin | -13.7% | -14.9% | -0.1% | -2.6% | 33.9% | 7.8% | 2.4% | 6.2% | -14.2% | 1.0% |
Source: Pacira BioSciences, Inc. SEC filings (10-K). 17 years of history available in the interactive view.
Explore 17 years of Pacira BioSciences, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track PCRX in your portfolio →
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.
Pacira BioSciences, Inc. — frequently asked questions
What is Pacira BioSciences, Inc.'s revenue?
Pacira BioSciences, Inc. (PCRX) reported revenue of $726.41M for fiscal year 2025, up 3.6% from the prior year, according to its SEC filings.
Is Pacira BioSciences, Inc. profitable?
Yes. PCRX earned net income of $7.03M in fiscal 2025, a net margin of 1.0%.
What is PCRX's P/E ratio?
Pacira BioSciences, Inc. trades at a price-to-earnings ratio of about 180.3 based on the latest data in our nightly-refreshed cache.
How fast is Pacira BioSciences, Inc. growing?
PCRX's revenue grew at roughly 11.1% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Pacira BioSciences, Inc.'s official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.